Abstract
30Nov 2016 TEYSUNO™ (S-1) IS BENEFICIAL FOR EGFR-TKI REFRACTORY NSCLC PATIENTS Feng Zhang , You Yu , Li-Na Xing and Min Chen. The department Cancer Radiation Oncology of the second affiliated Hospital of Harbin Medical University. The department of surgery of the first affiliated hospital of Harbin Medical University.
Highlights
Lung cancer is the leading cause of cancer-related global deaths with a five-year survival rate of 17% (1-3)
Our finding showed that non-small-cell lung carcinoma (NSCLC) patient quality of life is significantly improved by Teysuno therapy
Personalized therapy is highly attractive in cancer therapy due to a high degree of tumor heterogeneity, resulting in differential responses to treatments (14, 15)
Summary
Lung cancer is the leading cause of cancer-related global deaths with a five-year survival rate of 17% (1-3). More than 80% of lung cancer cases are classified as non-small-cell lung carcinoma (NSCLC) (4). 65% NSCLC patients already have advanced disease, and can not be properly treated by surgery (5). Standard therapy with platinum based chemotherapy agents results in median survival of only ten months (6), underscoring the need for novel targeted therapies for NSCLC patients. The tyrosine kinase receptor EGFR (epidermal growth factor receptor) is often overexpressed or mutated in NSCLC, making it an attractive target for therapy (7). While most patients initially respond well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), they develop resistance to therapy within 6 -12 months (8, 9). It is necessary to develop therapeutic strategies for patients with EGFR-TKI resistant NSCLC, few effective agents are available
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
